Literature DB >> 33160458

Prostaglandin D2: the end of a story or just the beginning?

Huib A M Kerstjens1, Reinoud Gosens2.   

Abstract

Entities:  

Year:  2020        PMID: 33160458     DOI: 10.1016/S2213-2600(20)30449-5

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  2 in total

1.  Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial.

Authors:  Jorge Maspero; Ioana Octavia Agache; Tadashi Kamei; Makoto Yoshida; Bryan Boone; James M Felser; Fernando Kawakami; Barbara Knorr; David Lawrence; Thomas Lehmann; Wei Wang; Andrew J Pedinoff
Journal:  Respir Res       Date:  2021-12-11

2.  Prostaglandin D2 metabolites activate asthmatic patient-derived type 2 innate lymphoid cells and eosinophils via the DP2 receptor.

Authors:  Saskia Carstensen; Christina Gress; Veit J Erpenbeck; Shamsah D Kazani; Jens M Hohlfeld; David A Sandham; Meike Müller
Journal:  Respir Res       Date:  2021-10-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.